25% healthcare staff infected despite taking 2 jabs in Delhi: Study

New Delhi: A little more than 25 per cent of healthcare workers were infected with coronavirus despite getting fully jabbed, a recent study has revealed, giving an insight on the breakthrough infections due to the Delta variant.

The study, jointly conducted by the Institute of Genomics and Integrative Biology (IGIB) and Max hospitals in Delhi-NCR, found that vaccination breakthroughs were far more common during the Delta-outbreak in Delhi than previously reported.

However, the severity of the infection was low and vaccination is crucial to avoid severe illnesses, said Shantanu Sengupta, senior scientist with the IGIB and one of the lead researchers of the study.

He also cautioned that of the 25 per cent who were infected, a large number were asymptomatic, so masking is also very important to arrest the spread of infection.

Sengupta said nearly 95 healthcare workers who had taken the two doses were studied. They were assessed from 45-90 days after their inoculation. Of the 95, more than 25 per cent saw breakthrough infections.

“Immunisation is expected to confer protection against infection and severe disease for vaccines, while reducing risks to non-immunised population by inhibiting transmission. Here, based on serial serological studies, we show that during a severe SARS-CoV2 Delta-variant outbreak in Delhi, 25.3 per cent of previously uninfected, ChAdOx1-nCoV19 (Covishield) double vaccinated, healthcare-workers (HCW) were infected within a period of less than two months, based on serology,” the study said.

Most infections were unrecognised. PTI

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India